Herbert J. Conrad

Herbert J. Conrad (board member) discloses dealings in 4 companies, chiefly Savient Pharmaceuticals Inc, Matinas BioPharma Holdings, Inc. and Celldex Therapeutics, Inc. Between 30 December 2005 and 22 June 2022, the trades on record add up to 103 filings.

On the open market, the record shows 2 purchases worth €130k and 24 sales worth €3.7M. On balance, insiders were net sellers of €3.6M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 35 share grants and 20 option exercises.

The record was last updated on 5 July 2022 with a transaction in Matinas BioPharma Holdings, Inc. The most recent open-market purchase was published on 20 May 2019, 2,713 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.